Introgen Therapeutics, Inc. (fka INGNQ)

[Welsh_Dragon]

Connecting the dots..

Seems to me that these INGNQ patents might be worth quite a bit..

(from Wikipedia)

http://en.wikipedia.org/wiki/Crucell

History

In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 milion in order to collaborate on the development of a flu vaccine.[3] This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011[4] and delisting the company from stock exchanges two months later.[5]



Adenovirus patent awarded to Introgen
By Anna Lewcock, 19-Dec-2006
Related topics: Materials & Formulation, Ingredients, excipients and raw materials

Introgen Therapeutics last week announced that it has been granted a European patent for the commercial production of adenoviral compositions.

Adenoviruses have immense potential as vectors in gene therapy and vaccination as they can be genetically altered in vitro to code for specific proteins, without producing pathogenic viral offspring.

The patent awarded to Introgen relates to the production of purified adenoviral compositions produced on a commercial scale, and that can be readily validated for regulatory purposes. Introgen has also been selected to manufacture the worldwide adenoviral reference material, which will be used by firms and institutions developing adenovirus-based products.

..

So should we be making money on stuff like this..

?
http://www.sirion-biotech.de/COM/technology/adenovirus.htm